findmyKOL

Parakkal Deepak, MD

Enriched profile

Professor of Medicine, Director of Clinical and Translational Research, Division of Gastroenterology, Co-Director of IBD Center · Washington University in St. Louis

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Saint Louis, MO · Midwest · United StatesSpecialtyGastroenterologyFocusInflammatory Bowel Disease+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceNone verifiedPayments2021–2025NIH fundingNone on fileWhy? →

Parakkal Deepak is Professor of Medicine, Director of Clinical and Translational Research, Division of Gastroenterology, Co-Director of IBD Center at Washington University in St. Louis. OpenAlex indexes 600 publications with 5,668 citations (h-index 35); ClinicalTrials.gov lists 11 registered studies with this person as an investigator.

Data verified 18 Oct 2026

Overview

Updated 18 Oct 2026

Parakkal Deepak, MD, is Professor of Medicine, Director of Clinical and Translational Research, Division of Gastroenterology, Co-Director of IBD Center at Washington University in St. Louis. The public record shows 600 publications with 5,668 citations (h-index 35), centered on Inflammatory Bowel Disease, Rheumatoid Arthritis Research and Therapies, Ocular Diseases and Behçet’s Syndrome. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 22 companies.

  • Most recent indexed publication: 2026 · Journal of medical economics
  • Top research focus: Inflammatory Bowel Disease
  • 11 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 22 companies

Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
IBD (Crohn's / UC)9 trialsCrohn Disease6 trialsColitis, Ulcerative3 trialsUlcer3 trialsColitis3 trialsObesity2 trialsOverweight2 trialsRheumatoid Arthritis

Research focus

OpenAlex concept fingerprint
Inflammatory Bowel DiseaseRheumatoid Arthritis Research and TherapiesOcular Diseases and Behçet’s SyndromeAnorectal Disease Treatments and OutcomesDiverticular Disease and Complications

Drugs & molecules

across trials, industry payments and publications
Skyrizigeneric · RisankizumabClinical trials—Industry payments16Publications2Xeljanzgeneric · TofacitinibClinical trials—Industry payments12Publications2Stelarageneric · UstekinumabClinical trials—Industry payments7Publications5Tremfyageneric · GuselkumabClinical trials—Industry payments50Publications—Rinvoqgeneric · UpadacitinibClinical trials—Industry payments23Publications—Zeposiageneric · OzanimodClinical trials—Industry payments17Publications—Gamifantgeneric · EmapalumabClinical trials—Industry payments10Publications—Velsipitygeneric · EtrasimodClinical trials—Industry payments6Publications—Zymfentrageneric · InfliximabClinical trials—Industry payments6Publications—Omvohgeneric · MirikizumabClinical trials—Industry payments5Publications—Humirageneric · AdalimumabClinical trials—Industry payments4Publications—Taltzgeneric · IxekizumabClinical trials—Industry payments3Publications—

Works with

trial sponsors and companies reporting payments
Eli Lilly and CompanyClinical trials2Industry payments8Janssen Biotech, Inc.Clinical trials—Industry payments45Abbvie Inc.Clinical trials—Industry payments41Celgene CorporationClinical trials—Industry payments14Pfizer Inc.Clinical trials—Industry payments12Sobi, IncClinical trials—Industry payments10Janssen Scientific Affairs, LLCClinical trials—Industry payments9Merck Sharp & Dohme LLCClinical trials—Industry payments9Celltrion USA Inc.Clinical trials—Industry payments6E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments5Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments5Boehringer Ingelheim International GmbHClinical trials—Industry payments3Washington University School of MedicineClinical trials3Industry payments—Hexal AGClinical trials—Industry payments2Lilly USA, LLCClinical trials—Industry payments2Mindray DS USA, Inc.Clinical trials—Industry payments2TakedaClinical trials2Industry payments—Alimentiv Inc.Clinical trials1Industry payments—Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments1Cordis Us Corp.Clinical trials—Industry payments1Cumberland Pharmaceuticals, Inc.Clinical trials—Industry payments1Exegi Pharma, LLCClinical trials1Industry payments—Fresenius Kabi USA, LLCClinical trials—Industry payments1Genentech, Inc.Clinical trials—Industry payments1NeuroLogica Corporation, a subsidiary of Samsung Electronics Co., Ltd.Clinical trials—Industry payments1PredictImmune LtdClinical trials1Industry payments—University of North Carolina, Chapel HillClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
600publications

Distinct works indexed by OpenAlex, matched via ORCID; 53 in PubMed.

5,668citations

Total citations across indexed works.

35h-index

Hirsch index (OpenAlex). i10-index 102.

Clinical & industry

trials, payments and federal funding
11clinical trials

Investigator role on registered studies.

View trials ↓
22companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

No public contact details on file. This person's NPPES record doesn't include a practice address or telephone number. Why? →

Clinical trials

Updated 18 Oct 2026

Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:

All 11 trial records: search, sort and filter.Explore →

Industry payments

Updated 18 Oct 2026

22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 41 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 18 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 53 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
    Article881 citations2021
    doi.org ↗
  2. 02
    Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2
    Article418 citations2021
    doi.org ↗
  3. 03
    Debaryomyces is enriched in Crohn’s disease intestinal tissue and impairs healing in mice
    Article218 citations2021
    doi.org ↗
  4. 04
    T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH Study
    Article218 citations2012
    doi.org ↗
  5. 05
    Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis
    Review192 citations2021
    doi.org ↗
All 600 cited works: search, sort and filter.Explore →

Network

Updated 18 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Matthew A. Ciorba109Eli D. Ehrenpreis77Andres J. Yarur73Derrick J. Stobaugh50Edward V. Loftus46David H. Ballard42David H. Bruining41Poonam M. Beniwal-Patel40Shrinivas Bishu36Siyan “Stewart” Cao36Joel R. Pekow35Jalpa Devi32Ryan C. Ungaro28Quazim A. Alayo28Jean‐Frédéric Colombel27Marco Colonna27Sami Samaan26George P. Christophi24Scott A. Mchenry24Edward L. Barnes24Joel G. Fletcher23Laura H. Raffals23Kaiming Ma22Malek Ayoub22Andres Yarur22Raymond Keith Cross21Marc Fenster21Jeff L. Fidler21Phil J. Tozer21Jaap Stoker20Anish A Patel20Amanda M. Johnson19Laura E. Raffals19Humberto Sifuentes19Maria Zulfiqar19Nicholas O. Davidson18Daniel R. Ludwig17GIL Y. MELMED17Anas K. Gremida16Jeffrey D. McCurdy16

Background & recognition

Updated 18 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MBBS

    Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India

    2004
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gastro.wustl.edu ↗
  • Board Certified in Gastroenterology
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →care.healthline.com ↗

Editorial & leadership roles

journal and society appointments

Secondary affiliations

appointments beyond the home institution
  • Crohn's and Colitis Foundation

    Deputy Director of Data Quality and Enhancement, SPARC-IBD

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gastro.wustl.edu ↗
  • TOpCLASS fistula consortium
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gastro.wustl.edu ↗
  • REBOOT IBD consortium

    co-founder

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gastro.wustl.edu ↗

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.